On the Trail of a New Killer

Progression of undiagnosed cutaneous lymphoma after anti–tumor necrosis factor-alpha therapy

“…It has been suggested that chronic lymphocyte-driven inflammatory states of psoriasis and atopic dermatitis plus the use of immunosuppressive therapies may help to select a malignant T-cell clone, provoking the development of CTCL. 28, 32 Controversy surrounds the true prevalence of CL in patients with atopic dermatitis and psoriasis. One group reported a significant increased risk of CTCL in patients with moderate to severe psoriasis independent of the systemic therapy received (adjusted hazard ratio of 9.25 [CI: 95%]).…”

Adnexotropic and granulomatous mycosis fungoides following TNF‐α inhibitor treatment

“…The present case adds to the body of literature on the interplay between psoriasis, TNF‐α inhibitor treatment, and MF. A number of studies have identified an increased prevalence of CTCL among psoriatic patients treated with TNF‐α inhibitors, although the underlying etiology is not well‐understood 4,5 . The duration between initiation of TNF‐α inhibitors and development of CTCL is variable ranging from 1 to 120 months.…”

“…A number of studies have identified an increased prevalence of CTCL among psoriatic patients treated with TNF-α inhibitors, although the underlying etiology is not well-understood. 4,5 The duration between initiation of TNF-α inhibitors and development of CTCL is variable ranging from 1 to 120 months. It has been proposed that the lymphocytic inflammation of psoriasis, along with the immune-modulating effects of TNF-α inhibitors, leads to the selection of malignant T-cell clones, increasing the risk of CTCL.…”